Document is current
Any future updates will be listed below
-
Authors
Ritchie, Scott C. https://orcid.org/0000-0002-8454-9548
Lambert, Samuel A. https://orcid.org/0000-0001-8222-008X
Arnold, Matthew https://orcid.org/0000-0001-6339-1115
Teo, Shu Mei
Lim, Sol https://orcid.org/0000-0001-7786-3355
Scepanovic, Petar
Marten, Jonathan
Zahid, Sohail
Chaffin, Mark https://orcid.org/0000-0002-1234-5562
Liu, Yingying
Abraham, Gad
Ouwehand, Willem H. https://orcid.org/0000-0002-7744-1790
Roberts, David J.
Watkins, Nicholas A.
Drew, Brian G. https://orcid.org/0000-0002-7839-9467
Calkin, Anna C. https://orcid.org/0000-0002-9861-0602
Di Angelantonio, Emanuele
Soranzo, Nicole https://orcid.org/0000-0003-1095-3852
Burgess, Stephen https://orcid.org/0000-0001-5365-8760
Chapman, Michael https://orcid.org/0000-0002-4582-6303
Kathiresan, Sekar https://orcid.org/0000-0002-3711-7101
Khera, Amit V.
Danesh, John
Butterworth, Adam S. https://orcid.org/0000-0002-6915-9015
Inouye, Michael https://orcid.org/0000-0001-9413-6520
- License Information
-
More Information
Article History
Received: 14 May 2021
Accepted: 14 September 2021
First Online: 8 November 2021
Competing interests
: Several authors are now employed by or run pharmaceutical companies. All significant contributions to this study were made before these roles and the named companies had no role in the study. M.A. is an employee of AstraZeneca. P.S. is an employee of Roche. J.M. is an employee of Genomics PLC. G.A. is an employee of CSL Limited. S.K. is the chief executive officer of Verve Therapeutics. The other authors declare no competing interests.
